10-Q · April 28, 2026
Design Therapeutics reported lower operating expenses in Q1 2026 with total operating expenses of $19.706 million, driven by a $998 thousand decline in R&D spend to $14.379 million and modestly higher G&A of $5.327…
Earnings analysis · 10-Q
DSGN earnings analysis
Filed August 3, 2026 · Our reading of the company's report
The latest report
Design Therapeutics remains a pre-revenue clinical-stage company, reporting a Q2 2026 EPS loss of $0.32, modestly better than the $0.34 loss a year ago but worse than the $0.29 loss in Q1. Liquidity of $207.4 million…
Read full summary
Design Therapeutics remains a pre-revenue clinical-stage company, reporting a Q2 2026 EPS loss of $0.32, modestly better than the $0.34 loss a year ago but worse than the $0.29 loss in Q1. Liquidity of $207.4 million and an additional $19.9 million raised through the ATM provide more than 12 months of planned funding, but six-month operating cash burn was $32.0 million and further capital will be needed before regulatory approval. The central catalyst is 12-week DT-216P2 RESTORE-FA data expected in Q1 2027; DT-168 data were delayed to 2027 due to packaging supply constraints.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.32
What stood out
-
EPS improved year over year, worsened sequentially
The Q2 diluted EPS loss was $0.32, improving by $0.02 from a $0.34 loss in Q2 2025, though worsening by $0.03 from a $0.29 loss in Q1 2026. The company has no approved products and reported no product-sale revenue.
-
Cash supports more than 12 months of operations
Cash, cash equivalents and investment securities were $207.4 million at June 30, 2026, down $12.4 million from $219.8 million at December 31, 2025. Management believes this balance funds planned operating expenses and capex for more than 12 months.
-
ATM bolstered liquidity amid operating cash burn
Six-month operating cash use was $32.0 million, versus $31.2 million a year earlier. The company raised approximately $19.9 million through the sale of 2,006,550 shares under its ATM program, leaving $53.9 million available under that facility.
-
R&D investment rose modestly for FA development
Q2 R&D expense increased 4% to $16.4 million from $15.7 million, driven by FA clinical activity and indirect costs, while G&A declined $0.04 million to $5.8 million. Total operating expense rose $0.6 million to $22.2 million.
-
Early DT-216P2 biomarker and clinical activity
In RESTORE-FA's 1 mpk cohort of 4 patients, four-week treatment produced mean improvements of 6.4 points in mFARS and 2.7 points in upright stability; whole-blood FXN mRNA increased 65%. No serious adverse events or discontinuations were reported.
-
Portfolio development advanced across FECD and DM1
The FECD observational study completed baseline assessments for approximately 250 patients and selected approximately 100 for follow-up. DM1 patient dosing began in the first half of 2026, expanding the clinical pipeline beyond FA.
What to watch
-
Ongoing losses require future capital
The company recorded a $37.8 million net loss and used $32.0 million in operating cash during the first six months of 2026. While it has $207.4 million of cash and securities, management states that current resources will not fund any product candidate through regulatory approval.
-
Supply constraints delayed DT-168 data
DT-168 Phase 2 biomarker-trial data are now expected in 2027 because of delayed supply of blow-fill-seal eye droppers. The company also reports only one supplier for an excipient component of DT-216P2, creating supply concentration risk.
-
Early clinical dataset and safety monitoring risk
RESTORE-FA's reported 1 mpk clinical results are based on only 4 patients and four weeks of treatment. Three patients had mild-to-moderate transient ALT elevations considered possibly or probably treatment-related, while 12-week data are not expected until Q1 2027.
-
Future financing may dilute shareholders
The company sold 2,006,550 shares for approximately $19.9 million through its ATM in the first half and retained $53.9 million of remaining ATM capacity. Further equity financing could dilute current holders as development spending grows.
-
Clinical expansion raises future spending risk
R&D expense is expected to increase as FA, FECD, DM1 and HD programs advance; Q2 R&D was already $16.4 million. The company had an accumulated deficit of $334.8 million as of June 30, 2026.
Management's outlook
No financial revenue or EPS guidance was provided. Management expects a DT-216P2 registrational-plan update in Q4 2026, 12-week RESTORE-FA data in Q1 2027, and DT-168 and DT-818 data in 2027.
Earlier filings 4
10-K · March 19, 2024
Design Therapeutics is an early-stage biopharma developing GeneTAC small molecules to address nucleotide repeat expansion diseases. The 10-K highlights program progress — IND clearance for DT-168 (FECD) in late 2023,…
10-Q · November 13, 2023
Design Therapeutics remains a pre-revenue biotech with a Q3 net loss per share of $0.28, a sequential and year-over-year improvement versus $0.32 in Q3 2022 and a beat to consensus (estimate -$0.41). The company has…
10-Q · May 9, 2023
Design Therapeutics reported a larger quarterly loss: net loss of $19,294 (‑$0.35 per share) in Q1 2023 versus $13,265 (‑$0.24) in Q1 2022, driven by higher operating expenses (total operating expenses $21,651 in Q1…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.